Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.78 |
| ▸ | HPGD | P15428 | 4/20 | 0.78 |
| ▸ | CASP1 | P29466 | 3/20 | 0.78 |
| ▸ | CASP7 | P55210 | 3/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.78 |
| ▸ | POLB | P06746 | 3/20 | 0.78 |
| ▸ | GLA | P06280 | 2/20 | 0.78 |
| ▸ | GAA | P10253 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.60 |
| ▸ | CA9 | Q16790 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15836702 | 0.88 | KMT2A (0.79) | KMT2AMEN1ALDH1A1HPGDCASP1 | |
| SCHEMBL15477297 | 0.88 | KMT2A (0.77) | KMT2AMEN1ALDH1A1HPGDCASP1 | |
| SCHEMBL15836708 | 0.87 | KMT2A (0.77) | KMT2AMEN1ALDH1A1HPGDCASP1 | |
| SCHEMBL12473143 | 0.85 | USP2 (0.74) | KMT2AMEN1ALDH1A1HPGDCASP1 | |
| SCHEMBL15836636 | 0.81 | KMT2A (0.72) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL15836700 | 0.80 | GAA (0.75) | KMT2AMEN1ALDH1A1HPGDCASP1 | |
| SCHEMBL466909 | 0.78 | CA12 (0.83) | KMT2AMEN1ALDH1A1HPGDKDM4E | |
| SCHEMBL15836707 | 0.74 | USP2 (0.71) | KMT2AMEN1ALDH1A1HPGDCASP1 | |
| Folescutol SCHEMBL554577 | 0.74 | TDP1 (0.81) | KMT2AMEN1ALDH1A1HPGDCASP1 | |
| SCHEMBL12473499 | 0.73 | KMT2A (1.00) | KMT2AMEN1ALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | KMT2A 3667/4885MEN1 3121/4885ALDH1A1 4348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.